KEYTRUDA® receives new approval from European Commission

KEYTRUDA® receives new approval from European Commission

On September 10, 2018, Keytruda® (pembrolizumab) received yet another approval. This time, the immunotherapy, in combination with Alimta® (pemetrexed) and platinum chemotherapy, was approved by the European Commission for the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumors have no EGFR or ALK positive mutations.

Read more

Previous

Next